Testosterone News and Research

Latest Testosterone News and Research

Enrollment complete in BioSante's LibiGel Phase III cardiovascular and breast cancer safety study

BioSante Pharmaceuticals, Inc., today announced completion of enrollment in its ongoing LibiGel (testosterone gel) Phase III cardiovascular and breast cancer safety study. LibiGel is in development for the treatment of female sexual dysfunction (FSD), specifically, hypoactive sexual desire disorder (HSDD) in menopausal women, for which there is no FDA-approved product.

31 May 2011

NEJM publishes ZYTIGA plus prednisone Phase 3 trial data in metastatic castration-resistant prostate cancer

A study titled "Abiraterone and Increased Survival in Metastatic Prostate Cancer," published in the May 26 issue of NEJM, found that patients with metastatic castration-resistant prostate cancer who have received prior chemotherapy containing docetaxel showed a significant improvement in overall survival when treated with ZYTIGA plus prednisone compared to patients treated with prednisone plus placebo.

26 May 2011

Pharmaceutical Executive's Ad Stars, DTC Perspectives recognize Auxilium and Heartbeat work

Heartbeat Ideas' and Auxilium Pharmaceuticals' ad campaign for Auxilium's Low Testosterone Therapy has been recognized as one of the top consumer advertisements of the year by Pharmaceutical Executive's Ad Stars and the DTC Perspectives National Ad Awards.

25 May 2011

Cell phones increase testosterone level, but decrease fertility in men

Men who have been diagnosed with poor sperm quality and who are trying to have children should limit their cell phone use. Researchers have found that while cell phone use appears to increase the level of testosterone circulating in the body, it may also lead to low sperm quality and a decrease in fertility.

20 May 2011

Obese men may face high risk of prostate cancer progression

Even when treated with hormone therapy to suppress tumor growth, obese men face an elevated risk of their prostate cancer worsening, researchers at Duke University Medical Center have found.

16 May 2011

Antares Pharma prices underwritten public offering of common stock

Antares Pharma, Inc. today announced it has priced a firm commitment underwritten public offering of 12,500,000 shares of the Company's common stock at a purchase price of $1.60 per share for an aggregate gross offering amount of $20.0 million.

13 May 2011

Long ring finger linked to Lou Gehrig’s disease

In some of the latest studies it has been found that finger length could be linked to various traits in people with amyotrophic lateral sclerosis, better known as ALS or Lou Gehrig’s disease. These people tend to have longer ring fingers, compared with their index fingers, than do people without the disease.

11 May 2011

Antares Pharma first quarter total revenues increase to $3.6 million

Antares Pharma, Inc. today reported financial and operating results for the first quarter ended March 31, 2011.

9 May 2011

GTx reports net loss of $2.6 million for first quarter 2011

GTx, Inc. today provided a company update and reported financial results for the first quarter of 2011.

9 May 2011

Columbia Laboratories net revenues increase 74% to $12.5 million

Columbia Laboratories, Inc. today reported financial results for the three-month period ended March 31, 2011.

5 May 2011

FDA approves new targeted therapy to treat men with advanced prostate cancer

The Food and Drug Administration on Thursday approved abiraterone, a new targeted therapy in the class of androgen receptor blockers.

3 May 2011

FDA approves Abbott's AndroGel for hypogonadism treatment in men

Abbott announced today that the U.S. Food and Drug Administration has approved AndroGel 1.62%, a clear, odorless, gel formulation shown to restore testosterone levels in hypogonadal men with half the volume of gel at the starting dose compared to AndroGel 1%.

30 Apr 2011

Centocor Ortho Biotech receives FDA approval for Zytiga to treat prostate cancer

The U.S. Food and Drug Administration today approved Zytiga in combination with prednisone to treat patients with late-stage castration-resistant prostate cancer who have received prior docetaxel.

28 Apr 2011

Close wins in sporting events linked to more traffic fatalities

When your team wins a close one, you may be in danger driving home after the game, according to a new study in the Journal of Consumer Research. The study shows that traffic fatalities rise near the hometowns of winning teams on game days.

22 Apr 2011

Acupuncture offers long-lasting relief for patients after prostate cancer treatment

Acupuncture provides long-lasting relief to hot flashes, heart palpitations and anxiety due to side effects of the hormone given to counteract testosterone, the hormone that induces prostate cancer, according to a study published in the April issue of the International Journal of Radiation Oncology-Biology-Physics, an official journal of the American Society for Radiation Oncology.

22 Apr 2011

Testosterone therapy for prostate cancer needs reevaluation: New study

The long-standing prohibition against testosterone therapy in men with untreated or low-risk prostate cancer merits reevaluation, according to a new study published in The Journal of Urology.

20 Apr 2011

BioSante, Aduro BioTech enter license agreement for GVAX cancer vaccines

Aduro BioTech, a clinical-stage immunotherapy company, has licensed GVAX Pancreas Cancer Vaccine and GVAX Prostate Cancer Vaccine BioSante Pharmaceuticals, Inc. in exchange for milestone and royalty payments after commercialization.

19 Apr 2011

BioSante licenses Pancreas and Prostate cancer vaccines to Aduro BioTech

BioSante Pharmaceuticals, Inc. today announced it has licensed its Pancreas Cancer Vaccine and Prostate Cancer Vaccine to Aduro BioTech, a clinical-stage immunotherapy company, solely for use in combination with Aduro's proprietary vaccine platform based on Listeria monocytogenes (Lm).

19 Apr 2011

FDA accepts Teva's NDA filing of Bio-T-Gel for male hypogonadism

BioSante Pharmaceuticals, Inc. today announced that a New Drug Application (NDA) has been accepted for filing by the U.S. Food and Drug Administration (FDA) following submission in January 2011 by a subsidiary of Teva Pharmaceutical Industries Ltd.. The FDA has assigned a PDUFA date of November 14, 2011. The PDUFA date is the target date for the FDA to complete its review of the NDA.

15 Apr 2011

Auxilium to receive $30 million from Pfizer following XIAPEX sale in EU market

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced that the Company will receive a $30 million regulatory milestone payment from its EU partner, Pfizer Inc., following the first sale of XIAPEX in a major EU market.

11 Apr 2011